Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Cost of Revenue: 2012-2025

Historic Cost of Revenue for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $24.5 million.

  • Veracyte's Cost of Revenue rose 8.15% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.0 million, marking a year-over-year increase of 3.32%. This contributed to the annual value of $95.4 million for FY2024, which is 5.97% down from last year.
  • Veracyte's Cost of Revenue amounted to $24.5 million in Q3 2025, which was down 3.40% from $25.3 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Cost of Revenue peaked at $26.1 million during Q1 2023, and registered a low of $16.3 million during Q1 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $24.5 million (2025), whereas its average is $24.6 million.
  • In the last 5 years, Veracyte's Cost of Revenue soared by 97.81% in 2021 and then declined by 8.99% in 2024.
  • Quarterly analysis of 5 years shows Veracyte's Cost of Revenue stood at $22.2 million in 2021, then rose by 8.62% to $24.1 million in 2022, then grew by 4.70% to $25.3 million in 2023, then declined by 1.73% to $24.8 million in 2024, then increased by 8.15% to $24.5 million in 2025.
  • Its Cost of Revenue stands at $24.5 million for Q3 2025, versus $25.3 million for Q2 2025 and $24.5 million for Q1 2025.